more_reports

The Latest Life Sciences Tools & Diagnostics Articles from Streetwise Reports

Biotech Expands Financing to CA$2M as AI-Driven Cancer Drug Programs Advance

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) increased its previously announced financing to approximately US$2.0 million through a convertible debenture and private placement. The company stated the proceeds will support working capital needs and ongoing corporate and strategic initiatives.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

AI Collaboration Expands to Accelerate Cancer Drug Discovery

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) has broadened its partnership with Variational AI to refine next-generation ATR inhibitors using generative AI. The agreement aims to streamline lead optimization for the company's kt-5000 series of small-molecule cancer drug candidates.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Expanded AI Collaboration Advances Optimization of Cancer Drug Candidates

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) has expanded its partnership with Variational AI to advance optimization of its kt-5000 ATR inhibitor series. Learn how the agreement deepens the company's use of generative AI to refine small-molecule drug candidates and accelerate preclinical selection.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Strategic Inflection: Scaling Multi-Condition Platform in Financial Transition

  ()
Current valuation disproportionately penalizes DarioHealth for balance sheet constraints while assigning negligible value to its contracted growth and superior margin profile. As the revenue from the 2025 bookings cohort begins to layer in during the first half of 2026, we anticipate a re-rating of the equity toward multiples consistent with its high-growth digital health peers.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Showing Results: 26 to 29 of 29 Prev